Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science. | At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are motivated by the power of science, with a legacy of pursuing bold science across oncology, hematology, cardiovascular, immunology and neuroscience. We’re accelerating the development of new medicines with differentiated research platforms and leading technology to define what’s possible for the future of medicine and the patients we serve.
BostonGene
BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and AI. Built and validated through an extensive real-world clinical testing network, BostonGene’s foundation model for tumor and immune biology integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners design and de-risk trials, identify novel targets, and optimize therapeutic response prediction while improving patient care through clinically integrated innovation.
Boehringer Ingelheim International GmbH
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.
Boehringer Ingelheim Pharmaceuticals
We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations. Read more here: https://www.boehringer-ingelheim.com/human-health/cancer | Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.us | At Boehringer Ingelheim we are driven by the desire to serve humankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our FOCUS articulates who we are and what we strive for, why we exist, how we work and what we want to achieve.
Boca Scientific Inc.
Boca Scientific Incorporated was established in 2002. We bring innovative Biotechnology products from around the world to research labs in the United States and Canada. We are proud to offer a carefully curated selection of leading-edge Molecular Biology, Immunology, Cell Biology, and Diagnostics products as well as our BOCARACK freezer storage systems. Our product offering includes a unique selection of research and diagnostic reagents, kits, and supplies both from our own-line, and from manufacturers in Europe, Asia, North America, and Australia. In addition to our BOCARACK and BocaBench product lines, we represent a number of well-established international companies including MoBiTec GmbH (Germany), Isohelix (United Kingdom), Candor Biosciences (Germany), OZ Biosciences (France), Bioron (Germany), Cell Culture Technologies (Switzerland), Intron Biotechnology (South Korea), EpitogenX (Scotland), GRiSP (Portugal), Agrisera Antibodies (Sweden), MethylDetect (Denmark), and more. We are proud to supply to a large base of higher education institutions, hospitals, research institutes, government agencies and private biotechnology, diagnostic, CROs, and pharmaceutical companies. Our customers include 10/10 of the top pharmaceutical companies, and 10/10 of the top Biotechnology companies in the US. Some of our key differentiators include the quality of products we bring to the market, our commitment to customer service and support, and our efficient operating practices which allow us to offer timely delivery of our products.
BLOOMAGE BIOTECHNOLOGY USA INC.
Bloomage (688363. SH) is a global biotechnology and biomaterial company founded in 2000. Driven by synthetic biotechnology, the company is engaged in the development, production and application of bioactive substances that are conducive to life and health, including functional sugars, proteins, polypeptides, amino acids, nucleotides, and natural active compounds. | Bloomage embarked on its journey in 2000, venturing into the production of hyaluronic acid through microbial fermentation. With over two decades of unwavering commitment and ceaseless innovation, Bloomage has established itself as a prominent global biotechnology and biomaterial company that specializes in the industrialization of hyaluronic acid. Bloomage is steadfastly dedicated to enhancing people’s quality of life by creating healthier experiences. Through its pioneering approach, the company strives to unlock the full potential of hyaluronic acid and revolutionize biotechnology.
BioRelo
BioRelo (Biological Relocation Solutions, LLC) is a nationwide lab moving company specializing in the safe, compliant transport and storage of temperature sensitive materials for life science organizations. Our team manages the relocation of biological materials, hazardous chemicals, infectious substances, and cold storage equipment while maintaining strict regulatory compliance and chain of custody. Our trucks operate as mobile cold rooms, supporting temperature controlled environments from ambient conditions to ultra low and cryogenic temperatures reaching -196°C. Our team has extensive experience managing the planning, transport, and delivery of ULT freezers, laboratory refrigerators, and liquid nitrogen storage systems. In addition to relocation services, BioRelo operates a secure biorepository facility offering both short term and long term storage solutions for biological samples, research materials, and clinical specimens.
BioNTech
As a global biotechnology company, our fully integrated business model includes basic scientific research, translational drug discovery, clinical development, GMP (Good Manufacturing Practices) compliant manufacturing and commercialization. With our patient-centered treatment approaches, we aim to become a leading biotechnology company in the fields of oncology and infectious diseases.
BioMetas
Based in Shanghai with a presence in Boston, Massachusetts, BioMetas leverages decades of expertise to provide robust biological assays for pharmaceutical and biotech companies. With a strong foundation in CRO and early-discovery services, our customer-first approach ensures high-quality data delivered with rapid turnaround times. Through our validated in vitro and in vivo biological assays, we support the advancement of therapies that advance your discovery programs forward. BioMetas is dedicated to supporting your project team, saving you time to focus on discovering therapeutic agents that benefit patient communities.
Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab/RenLite®/RenNano®/RenTCR-mimic) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg).